WO1996011279A3 - Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system - Google Patents

Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system Download PDF

Info

Publication number
WO1996011279A3
WO1996011279A3 PCT/US1995/012638 US9512638W WO9611279A3 WO 1996011279 A3 WO1996011279 A3 WO 1996011279A3 US 9512638 W US9512638 W US 9512638W WO 9611279 A3 WO9611279 A3 WO 9611279A3
Authority
WO
WIPO (PCT)
Prior art keywords
gene
recombinant virus
immune response
introduction
costimulatory molecule
Prior art date
Application number
PCT/US1995/012638
Other languages
French (fr)
Other versions
WO1996011279A2 (en
Inventor
Steven A Rosenberg
Nicholas P Restifo
Bernard Moss
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Priority to EP95938706A priority Critical patent/EP0789774A2/en
Priority to AU39982/95A priority patent/AU712714B2/en
Publication of WO1996011279A2 publication Critical patent/WO1996011279A2/en
Publication of WO1996011279A3 publication Critical patent/WO1996011279A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention is a recombinant virus which has incorporated into its genome or portion thereof a gene encoding an antigen at a disease causing agent in combination with an immunostimulatory molecule for the purpose of stimulating an immune response against the disease causing agent. Methods of treatment of diseases such as cancer and diseases caused by pathogenic microorganisms are provided using the recombinant virus.
PCT/US1995/012638 1994-10-03 1995-10-02 Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system WO1996011279A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP95938706A EP0789774A2 (en) 1994-10-03 1995-10-02 Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system
AU39982/95A AU712714B2 (en) 1994-10-03 1995-10-02 Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule B7 gene in a recombinant virus expressing system

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US31740294A 1994-10-03 1994-10-03
US08/317,402 1994-10-03
US47463995A 1995-06-07 1995-06-07
US08/474,639 1995-06-07

Publications (2)

Publication Number Publication Date
WO1996011279A2 WO1996011279A2 (en) 1996-04-18
WO1996011279A3 true WO1996011279A3 (en) 1996-05-17

Family

ID=26980930

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/012638 WO1996011279A2 (en) 1994-10-03 1995-10-02 Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system

Country Status (4)

Country Link
EP (1) EP0789774A2 (en)
AU (1) AU712714B2 (en)
CA (1) CA2201592A1 (en)
WO (1) WO1996011279A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9005602B2 (en) 2006-10-16 2015-04-14 Genelux Corporation Modified vaccinia virus strains for use in diagnostic and therapeutic methods
US9492534B2 (en) 2003-06-18 2016-11-15 Genelux Corporation Microorganisms for therapy

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6816194A (en) * 1993-04-20 1994-11-08 Robinson, William S. Methods and materials for treatment of individuals infected with intracellular infectious agents
WO1998008947A1 (en) * 1995-12-19 1998-03-05 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Enhancement of dna immunization through the use of cytokines
CA2261990A1 (en) * 1996-07-25 1998-02-05 Therion Biologics Corporation Recombinant pox virus for immunization against tumor-associated antigens
EP2112225A1 (en) * 1996-07-25 2009-10-28 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Recombinant pox virus for immunization against tumor-associated antigens
FR2751879B1 (en) * 1996-07-30 1998-10-30 Transgene Sa PHARMACEUTICAL COMPOSITION AGAINST TUMORS AND PAPILLOMAVIRUS INFECTIONS
CN1257976C (en) * 1996-10-23 2006-05-31 宾夕法尼亚州立大学托管会 Immunotherapy and improved vaccines
US6077833A (en) * 1996-12-31 2000-06-20 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US6319906B1 (en) 1996-12-31 2001-11-20 Isis Pharmaceuticals Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US7235653B2 (en) 1996-12-31 2007-06-26 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
AU5805798A (en) * 1996-12-31 1998-07-31 Wistar Institute, The Recombinant adenoviral vector expressing antigens associated with colorectal tumors
US6730512B2 (en) 1997-04-09 2004-05-04 Amdl, Inc. Combination immunogene therapy
WO1998044788A2 (en) * 1997-04-09 1998-10-15 Chang Lung Ji Animal model for evaluation of vaccines
EP1518927A3 (en) * 1998-02-11 2005-06-22 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
EP1056842A2 (en) * 1998-02-11 2000-12-06 Maxygen, Inc. Genetic vaccine vector engineering
ATE512231T1 (en) * 1998-02-27 2011-06-15 Univ Pennsylvania VACCINES, IMMUNOTHERAPEUTICS AND METHODS FOR USING THE SAME
EP1073749B1 (en) * 1998-04-22 2006-01-11 Chiron Corporation Enhancing immune responses to genetic immunization by using a chemokine
US6919318B1 (en) 1998-04-22 2005-07-19 Chiron Corporation Enhancing immune responses to genetic immunization by using a chemokine
US6734172B2 (en) * 1998-11-18 2004-05-11 Pacific Northwest Research Institute Surface receptor antigen vaccines
US7148035B1 (en) 1998-11-18 2006-12-12 Oxford Biomedica (Uk) Limited Polypeptide
MXPA01011079A (en) 1999-04-30 2002-07-22 Univ Pennsylvania Mutant human cd80 and compositions for and methods of making and using the same.
ATE391726T1 (en) 1999-10-22 2008-04-15 Sanofi Pasteur Ltd MODIFIED GP100 AND ITS USE
US7361329B2 (en) 2000-04-21 2008-04-22 Chemocentryx, Inc. Compositions for inducing an immune response
EP1741782B1 (en) 2000-05-10 2011-06-22 Sanofi Pasteur Limited Immunogenic polypeptides encoded by MAGE minigenes and uses thereof
US7754201B2 (en) 2000-06-02 2010-07-13 GenPhar, Inc Method of vaccination through serotype rotation
US6544780B1 (en) * 2000-06-02 2003-04-08 Genphar, Inc. Adenovirus vector with multiple expression cassettes
US20020155127A1 (en) * 2000-06-02 2002-10-24 Danher Wang Genetic vaccine against human immunodeficiency virus
JP2004507231A (en) * 2000-06-15 2004-03-11 アメリカ合衆国 Recombinant non-replicating virus expressing GM-CSF and use thereof for enhancing an immune response
US7092633B2 (en) 2000-11-14 2006-08-15 University Of Texas System Board Of Regents System and method for configuring optical circuits
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
EP1864691B1 (en) 2002-04-09 2011-07-20 Sanofi Pasteur Limited Modified CEA nucleic acid and expression vectors
AU2004280608B2 (en) 2002-04-09 2012-04-05 Sanofi Pasteur, Inc. Modified CEA/B7 vector
EP1563074B1 (en) 2002-11-12 2018-01-10 VAXum, LLC. Adenoviral vector vaccine
US8663622B2 (en) 2002-12-16 2014-03-04 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Recombinant vaccine viruses expressing IL-15 and methods using the same
US7960355B2 (en) 2003-05-23 2011-06-14 Isis Pharmaceuticals, Inc. Compositions and methods for the modulation of the expression of B7 protein
US7897582B2 (en) 2003-05-23 2011-03-01 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
EP1526185B1 (en) * 2003-10-22 2012-09-12 Genelux Corporation Use of a microorganism or cell to induce autoimmunization of an organism against a tumor
EP1660119A2 (en) * 2003-09-05 2006-05-31 Sanofi Pasteur Limited Multi-antigen vectors for melanoma
CA2544946A1 (en) 2003-11-24 2005-03-06 Sidney Kimmel Cancer Center Mucin antigen vaccine
US8828957B2 (en) 2003-12-11 2014-09-09 Microvax, Llc Methods for generating immunity to antigen
CA2687688C (en) * 2007-05-23 2017-03-28 Sangamo Biosciences, Inc. Methods and compositions for increased transgene expression in t cells
CA2787099A1 (en) 2009-03-30 2010-10-14 Anice C. Lowen Influenza virus hemagglutinin polypeptides containing stem domains, vaccines and uses thereof
JP2013526849A (en) 2010-03-30 2013-06-27 モウント シナイ スクール オフ メディシネ Influenza virus vaccine and use thereof
EP4241785A3 (en) 2011-09-20 2023-09-27 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
NZ627796A (en) 2012-12-18 2017-07-28 Icahn School Med Mount Sinai Influenza virus vaccines and uses thereof
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
US10736956B2 (en) 2015-01-23 2020-08-11 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
CN109641041A (en) 2016-06-15 2019-04-16 西奈山伊坎医学院 Influenza virus haemagglutinin albumen and application thereof
CA3058652A1 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994016716A1 (en) * 1993-01-21 1994-08-04 Virogenetics Corporation Recombinant virus immunotherapy
WO1994024267A1 (en) * 1993-04-20 1994-10-27 Robinson, William, S. Methods and materials for treatment of individuals infected with intracellular infectious agents
US7122163B2 (en) * 2000-06-12 2006-10-17 Japan Science And Technology Agency Rare-earth oxide or sulfide of nano size and process for producing the same through photochemical reaction

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994016716A1 (en) * 1993-01-21 1994-08-04 Virogenetics Corporation Recombinant virus immunotherapy
WO1994024267A1 (en) * 1993-04-20 1994-10-27 Robinson, William, S. Methods and materials for treatment of individuals infected with intracellular infectious agents
US7122163B2 (en) * 2000-06-12 2006-10-17 Japan Science And Technology Agency Rare-earth oxide or sulfide of nano size and process for producing the same through photochemical reaction

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 8837, Derwent World Patents Index; Class B04, AN 88-264270 *
J.RUBY ET AL.: "Response of monkeys to vaccination with recombinant vaccinia virus which coexpress HIV gp160 and human interleukin-2", IMMUNOLOGY AND CELL BIOLOGY, vol. 68, CARLTON, AU, pages 113 - 117 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9492534B2 (en) 2003-06-18 2016-11-15 Genelux Corporation Microorganisms for therapy
US9005602B2 (en) 2006-10-16 2015-04-14 Genelux Corporation Modified vaccinia virus strains for use in diagnostic and therapeutic methods

Also Published As

Publication number Publication date
CA2201592A1 (en) 1996-04-18
WO1996011279A2 (en) 1996-04-18
EP0789774A2 (en) 1997-08-20
AU3998295A (en) 1996-05-02
AU712714B2 (en) 1999-11-11

Similar Documents

Publication Publication Date Title
WO1996011279A3 (en) Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system
WO1996010419A3 (en) Composition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule
DE69536039D1 (en) A host cell containing a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule
EP0835133A4 (en) Recombinant poxvirus-rabies compositions and combination compositions and uses
CY2570B1 (en) Compounds for immunotherapy and diagnosis of tuberculosis
WO2002034205A3 (en) Using heat shock proteins to increase immune response
CA2132836A1 (en) Immunization by inoculation of dna transcription unit
GR3020557T3 (en) Oligonucleotide alkylphosphonates and alkylphosphonothioates.
MY125202A (en) Vaccine
WO1998055495A3 (en) Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
WO2001034801A3 (en) Recombinant gelatin in vaccines
WO1998037095A3 (en) Recombinant pox virus for immunization against muc1 tumor-associated antigen
WO1998053075A3 (en) Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
CA2109977A1 (en) Giardia vaccines
WO1997004099A3 (en) Papillomaviruses, agents for detecting them and for treating diseases caused by such viruses
WO1996040764A3 (en) Nucleotide and amino acid sequences of hypervariable region 1 of the envelope 2 gene of hepatitis c virus
WO1998023752A3 (en) Papilloma viruses, agents for detecting the same and for treating diseases caused by such viruses
WO1999009177A3 (en) Papilloma virus, agents for the detection thereof and for the therapy of the diseases caused by said virus
AU5489500A (en) Isolation of a human retrovirus
WO1998042847A3 (en) Papilloma virus main capsid protein and the use thereof in diagnosis, therapy and vaccination
WO2000062817A3 (en) Inducible vaccines
NZ331889A (en) Trypanosomatids histones for use as an antigen against trypanosomatic infection, including diagnostic tests, pharmaceutical compositions and vaccines of these antigens
AU4300700A (en) Inactivated cytokines for immunisation
WO1996002272A3 (en) Treatment of autoimmune diseases
WO2000062816A3 (en) Genetic tolerization

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2201592

Country of ref document: CA

Ref country code: CA

Ref document number: 2201592

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1995938706

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1995938706

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1995938706

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995938706

Country of ref document: EP